Historical Valuation
Pacira Biosciences Inc (PCRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.12 is considered Undervalued compared with the five-year average of 12.83. The fair price of Pacira Biosciences Inc (PCRX) is between 165.90 to 198.96 according to relative valuation methord. Compared to the current price of 26.02 USD , Pacira Biosciences Inc is Undervalued By 84.32%.
Relative Value
Fair Zone
165.90-198.96
Current Price：26.02
84.32%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Pacira Biosciences Inc (PCRX) has a current Price-to-Book (P/B) ratio of 1.45. Compared to its 3-year average P/B ratio of 1.61 , the current P/B ratio is approximately -10.08% higher. Relative to its 5-year average P/B ratio of 2.51, the current P/B ratio is about -42.39% higher. Pacira Biosciences Inc (PCRX) has a Forward Free Cash Flow (FCF) yield of approximately 11.80%. Compared to its 3-year average FCF yield of 12.92%, the current FCF yield is approximately -8.67% lower. Relative to its 5-year average FCF yield of 8.96% , the current FCF yield is about 31.69% lower.
P/B
Median3y
1.61
Median5y
2.51
FCF Yield
Median3y
12.92
Median5y
8.96
Competitors Valuation Multiple
AI Analysis for PCRX
The average P/S ratio for PCRX competitors is 2.76, providing a benchmark for relative valuation. Pacira Biosciences Inc Corp (PCRX.O) exhibits a P/S ratio of 1.34, which is -51.45% above the industry average. Given its robust revenue growth of 6.49%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PCRX
1Y
3Y
5Y
Market capitalization of PCRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PCRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PCRX currently overvalued or undervalued?
Pacira Biosciences Inc (PCRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.12 is considered Undervalued compared with the five-year average of 12.83. The fair price of Pacira Biosciences Inc (PCRX) is between 165.90 to 198.96 according to relative valuation methord. Compared to the current price of 26.02 USD , Pacira Biosciences Inc is Undervalued By 84.32% .
What is Pacira Biosciences Inc (PCRX) fair value?
PCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Pacira Biosciences Inc (PCRX) is between 165.90 to 198.96 according to relative valuation methord.
How does PCRX's valuation metrics compare to the industry average?
The average P/S ratio for PCRX's competitors is 2.76, providing a benchmark for relative valuation. Pacira Biosciences Inc Corp (PCRX) exhibits a P/S ratio of 1.34, which is -51.45% above the industry average. Given its robust revenue growth of 6.49%, this premium appears unsustainable.
What is the current P/B ratio for Pacira Biosciences Inc (PCRX) as of Jan 09 2026?
As of Jan 09 2026, Pacira Biosciences Inc (PCRX) has a P/B ratio of 1.45. This indicates that the market values PCRX at 1.45 times its book value.
What is the current FCF Yield for Pacira Biosciences Inc (PCRX) as of Jan 09 2026?
As of Jan 09 2026, Pacira Biosciences Inc (PCRX) has a FCF Yield of 11.80%. This means that for every dollar of Pacira Biosciences Inc’s market capitalization, the company generates 11.80 cents in free cash flow.
What is the current Forward P/E ratio for Pacira Biosciences Inc (PCRX) as of Jan 09 2026?
As of Jan 09 2026, Pacira Biosciences Inc (PCRX) has a Forward P/E ratio of 7.12. This means the market is willing to pay $7.12 for every dollar of Pacira Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Pacira Biosciences Inc (PCRX) as of Jan 09 2026?
As of Jan 09 2026, Pacira Biosciences Inc (PCRX) has a Forward P/S ratio of 1.34. This means the market is valuing PCRX at $1.34 for every dollar of expected revenue over the next 12 months.